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ABSTRACT We have used a combination of hydropathy
analysis of the intercellular adhesion molecule 1 (ICAM-1)
sequence and dot-matrix comparison of the sequence with the
homologous, but functionally distinct, protein myelin-
associated glycoprotein to identify a putative functional binding
region. One polar, and presumably surface-exposed, region of
ICAM-1 showed no significant identity with myelin-associated
glycoprotein. A synthetic peptide analog based on the sequence
of this region (JF9) mimicked the inhibitory effects of the
anti-ICAM-1 monoclonal antibody WEHI-CAM-1. These in-
cluded inhibition of ICAM-1-dependent homotypic aggrega-
tion of Raji Burkitt lymphoma and phorbol-ester treated U937
cells at concentrations as low as 80 pg/ml (24 pzM). In
addition, at a concentration of 100 pg/ml, the peptide analog
effectively inhibited cytotoxic cell activity, an ICAM-1-
dependent effector function of the immune response. This
simple method of sequence analysis may have general appli-
cability to the identification of functional domains in homolo-
gous, but functionally distinct, proteins such as the translated
products of gene families.
The specific interaction between the two cell surface mole-
cules intercellular adhesion molecule 1 (ICAM-1, CD54) and
leukocyte function-associated antigen 1 (LFA-1, CD11a/
CD18) has been shown to be a major adhesive mechanism in
cells of the immune and hemopoietic systems (1). ICAM-1 is
a 90-kDa integral membrane glycoprotein, with an extracel-
lular region divided into five immunoglobulin-like domains of
the C2 type, a transmembrane region, and a short cytoplas-
mic tail (2, 3). On the basis of these data and other structural
similarities, ICAM-1 has been included in the immunoglob-
ulin supergene family (2-4). The receptor for ICAM-1,
LFA-1, belongs to the structurally different family ofproteins
termed integrins (5). The integrins are heterodimeric pro-
teins, a number of which bind to an Arg-Gly-Asp motif in
their ligands (6). There is no Arg-Gly-Asp sequence in
ICAM-1 (2, 3), nor does the Gly-Arg-Gly-Asp-Ser-Pro pep-
tide inhibit ICAM-1/LFA-1 binding (5-7).
To find amino acid sequences of possible functional im-
portance within the ICAM-1 sequence, we compared a hy-
dropathy analysis (8) of ICAM-1 with a dot-matrix sequence
comparison (9) of ICAM-1 with the homologous but func-
tionally distinct protein myelin-associated glycoprotein
(MAG). We report the identification of a polar region within
the fourth domain of the ICAM-1 sequence, which is pre-
sumably surface-exposed and shows minimal identity with
MAG. We also show that a synthetic peptide analog based on
this sequence mimics the effects of anti-ICAM-1 antibody in
bioassays dependent upon ICAM-1/LFA-1-mediated adhe-
sion.
MATERIALS AND METHODS
Sequence Analysis. Hydropathy analysis of the ICAM-1
sequence was performed using the Kyte-Doolittle algorithm
(8) with a window setting of 7 residues. Dot-matrix sequence
comparisons were performed by using the method of Maizel
and Lenk (9). Protein sequences were compared for simple
identity versus nonidentity scoring of amino acids with a
comparison length setting of 10 amino acids and a minimum
match score of 4. The FASTA program (10) was used for short
sequence homology searches of the NBRF, PRF-Japan,
Swiss-Prot, and GenBank (translated) data bases$ with a
stringency set initially at ktup = 2 followed by ktup = 1.
Synthesis of Peptides. Peptides were synthesized using
4-methylbenzhydrylamine resin (United States Biochemi-
cal), or PAM-t-Boc-L-Pro resin (Applied Biosystems; PAM =
4-(oxymethyl)phenylacetamidomethyl, t-Boc = t-butoxycar-
bonyl) on an Applied Biosystems 430A automated peptide
synthesizer using optimized solid-phase t-Boc chemistry
protocols (11). An average coupling efficiency of >99.3% as
determined by quantitative ninhydrin analysis (12) was
achieved in all syntheses. After standard deprotection and
HF cleavage from the resins (13), all peptides were purified
to >95% by preparative reverse-phase HPLC using an Aqua-
pore C8 100 x 10 mm 20-Itm Prep 10 cartridge column and
analyzed on Aquapore RP-300 C18 30 x 4.6 mm cartridge
columns (Applied Biosystems). All peptides were character-
ized with respect to purity and complete covalent structure
by analysis on a Sciex API-Ill mass spectrometer. Aqueous
stocks of HPLC-pure peptides were sterilized by 0.22-,um
filtration before use in the in vitro assays.
Monoclonal Antibodies. WEHI-CAM-1 and WEHI-B2 are
both IgG2b monoclonal antibodies which recognize CD54/
ICAM-1 (14) and CD21 (15), respectively. Both were purified
on staphylococcal protein A-Sepharose 4B CL (Pharmacia)
and eluted from the column with 0.1 M acetic acid, pH 3.0.
Purity of the recovered antibodies was confirmed by SDS/
polyacrylamide gel electrophoresis.
Cell Lines. All cell lines were maintained in RPMI 1640
medium supplemented with 10% (vol/vol) fetal calf serum.
Abbreviations: ICAM-1, intercellular adhesion molecule 1; LFA-1,
leukocyte function-associated antigen 1; MAG, myelin-associated
glycoprotein.
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Raji is a cell line derived from a Burkitt lymphoma patient and
has previously been shown to express both ICAM-1 and
LFA-1 (1). GM209, a self-aggregating ICAM-1-negative small
cell carcinoma line was generously provided by J. Layton
(Ludwig Institute of Cancer Research, Melbourne). U937
cells were treated with phorbol 12-myristate 13-acetate (Sig-
ma) to induce ICAM-1 expression as described previously
(16, 17).
Aggregation Assay. HPLC-pure peptides (0-500 ,ug/ml)
were added to 50,000 deaggregated Raji cells in RPMI
1640/5% (vol/vol) fetal calf serum in microtiter plate wells.
Aggregation was assessed by microscopy over a 24-hr period.
All scoring was performed by an observer who was blinded
to the experimental design.
Cytotoxic Cell Assay. Peripheral blood mononuclear cells
were activated in a two-way mixed lymphocyte response
between two normal unrelated donors. The cells (106 per ml)
were mixed in a 1:1 ratio and cultured in RPMI 1640/10%
fetal calf serum for 4 days. Recombinant interleukin 2 (Cetus)
was added (200 units/ml) and the cultures were continued for
a further 3 days. Cells were harvested and added to a constant
number (104 cells per well) of 51CrO4-labeled K562 cells in a
96-well microtiter tray. 51Cr release into the culture super-
natants was measured after 4 hr.
RESULTS
Analysis of the ICAM-1 Sequence. The ICAM-1 sequence
was first analyzed by using the Kyte-Doolittle hydropathy
algorithm to predict hydrophilic potential binding regions (8).
In Fig. 1A it can be seen that there are a number of predicted
hydrophilic regions with hydropathy indices as low as -3.4,
which contain clusters of both positive and negative charges.
These polar regions are likely to be exposed on the surface.
The next step was to define which of these regions were
most likely to be functional binding sites unique to ICAM-1.
To do this, we sought such unique regions by a dot-matrix
sequence comparison of ICAM-1 with the functionally dis-
tinct but homologous protein MAG (2, 19). Simple identity-
versus-nonidentity scoring of amino acids is shown in the
dot-matrix plot in Fig. 1B. A detailed analysis of the resulting
plot revealed a region within the ICAM-1 sequence that had
essentially no identity with MAG. This region spanned amino
acid residues 369-391 and is indicated by a virtual absence of
either isolated dots or strings of dots on the plot shown in Fig.
1B. When this sequence was analyzed in conjunction with the
hydropathy plot data, there was a striking correspondence to
a predicted polar surface region of the ICAM-1 sequence.
The uniqueness of this region of ICAM-1 (369-391) was
further confirmed by FASTA short sequence homology
searches (10) of a number of data bases with a stringency set
initially at ktup = 2 followed by ktup = 1. These searches
revealed no protein sequences with any significant identity to
the ICAM-1 369-391 sequence (10).
Design and Synthesis of Peptides. Having defined this
unique surface-exposed region of ICAM-1, we speculated
that this may be critical for binding to LFA-1. To experi-
mentally test this prediction, a 28-residue peptide analog
spanning this sequence (JF9, 367-394 with Cys-378 replaced
with Ala) and two control peptides of similar size, corre-
sponding to the N and C termini (JF7B, 1-23; and JF13A,
479-507, respectively), were prepared by total chemical
synthesis (Table 1). After purification and characterization,
these peptides were tested for their ability to interfere with
ICAM-1-mediated adhesion in several functionally distinct
biological systems.
Effects of Synthetic Peptides on ICAM-1-Mediated Adhe-
sion. Previous studies have shown that the anti-ICAM-1
monoclonal antibody WEHI-CAM-1 completely inhibits the
homotypic aggregation of the Raji Burkitt lymphoma cell line
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FIG. 1. Hydropathy and dot-matrix comparative sequence anal-
ysis of ICAM-1. The horizontal axes (residue number) of the two
plots are to the same scale. (A) Hydropathy plot of ICAM-1 accord-
ing to the method of Kyte and Doolittle (8) with a window setting of
7 residues. Negative numbers represent polar, presumably surface-
exposed, regions of the polypeptide chain. (B) Dot-matrix sequence
comparison of ICAM-1 (2, 3) with its homolog MAG (19), by the
method of Maizel and Lenk (9). The sequences were compared for
simple identity-versus-nonidentity scoring of amino acids with a
comparison length setting of 10 amino acids and a minimum match
score of 4. The lines extending from the dot matrix plot to the
hydropathy plot indicate the correspondence between the region of
nonidentity between the ICAM-1 and MAG sequences to a predicted
polar and thus likely surface-exposed region of the ICAM-1 mole-
cule.
(14). This effect could be reproduced with anti-LFA-1 anti-
bodies (5), implying that the ICAM-1/LFA-1 linkage is
critical for Raji cell aggregation. Testing of all three synthetic
peptides over a concentration range of 0-500 ,ug/ml in the
aggregation assay (see Materials and Methods) indicated that
the ICAM-1 peptide based on the "unique" sequence (JF9)
completely inhibited Raji cell aggregation at a concentration
as low as 24 ,uM, while the two control peptides had no
detectable inhibitory effect even at concentrations of 500
tug/ml (220 ALM). Typical results are shown in Fig. 2. On the
basis of a large number of experiments, we estimate that the
IC50 value for the JF9 peptide lies in the range of 3-10 .uM.
Preliminary experiments with another ICAM-1 peptide ana-
log (JF11, 415-439) also show no inhibitory effect on aggre-
gation (data not shown). A time course study of the inhibition
of cell aggregation by the JF9 peptide showed that the peptide
still had significant inhibitory activity after 48 hr. The same
pattern of inhibition was observed when the peptides were
tested in an aggregation assay of phorbol myristate acetate-
induced U937 cells (16, 17) (data not shown). In addition,
homotypic aggregation of an ICAM-1-negative small cell
carcinoma line, GM209, was not inhibited by any of the test
peptides or by WEHI-CAM-1 antibody. None ofthe peptides
were cytotoxic in any of the assays used in this work in the
concentration ranges tested.
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Table 1. Synthetic peptide analogs of ICAM-1
Region of
Peptide ICAM-1 spanned* Sequence
JF7B 1-23 Asn-Ala-Gln-Thr-Ser-Val-Ser-Pro-Ser-Lys-Val-Ile-Leu-Pro-Arg-Gly-Gly-Ser-Val-Leu-Val-Thr-Cys-NH2
JF9 367-394, [Ala-378] Val-Leu-Tyr-Gly-Pro-Arg-Leu-Asp-Glu-Arg-Asp-Ala-Pro-Gly-Asn-Trp-Thr-Trp-Pro-Glu-Asn-Ser-Gln-GIn-
Thr-Pro-Met-Cys-NH2
JF13A 479-507 Asn-Arg-Gln-Arg-Lys-Ile-Lys-Lys-Tyr-Arg-Leu-Gln-Gln-Ala-Gln-Lys-Gly-Thr-Pro-Met-Lys-Pro-Asn-Thr-
Gln-Ala-Thr-Pro-Pro-OH
*According to the sequence described by Simmons et al. (3).
Effects of Synthetic Peptides on ICAM-l-Dependent Cell-
Mediated Cytotoxicity. Our previous studies with the WEHI-
CAM-1 antibody have shown that ICAM-1 is essential for a
number of cell-cell contact-mediated immune responses (14).
Testing of the JF9 peptide and control peptides in a cytotoxic
cell assay over a concentration range of 0-250 ,gg/ml dem-
onstrated that the JF9 peptide was able to effectively inhibit
cell-mediated killing of the K562 erythroid cell line at a
concentration as low as 30 kLM (100 ,g/ml) (refer to Fig. 3).
In contrast, the two control peptides had little or no effect on
cytotoxic cell activity, even at a concentration of 250 ,gg/ml.
DISCUSSION
Using a combination of amino acid sequence hydropathy
analysis and sequence comparison programs, we have iden-
tified a potential binding region in the ICAM-1 sequence (Fig.
1). We have shown that a synthetic peptide analog based on
this sequence can interfere with ICAM-1-dependent pro-
cesses in vitro (Figs. 2 and 3). In particular, the results
obtained from the aggregation studies show that the JF9
peptide inhibits ICAM-1-dependent aggregation of cells, but
not ICAM-1-independent aggregation (Fig. 2). Moreover, the
JF9 peptide inhibits cytotoxic cell-mediated killing of K562
cells (Fig. 3), a process previously shown to require cell-cell
contact mediated by the ICAM-1/LFA-1 interaction (14). In
contrast, peptides JF7B and JF13A had no inhibitory effects
in this assay. These results suggest that we have identified a
functional binding domain within the ICAM-1 sequence.
It is of interest that the active synthetic peptide analog used
in this work corresponds to a sequence located within the
predicted fourth immunoglobulin-like domain (D4) on the
ICAM-1 molecule (2). Staunton et al. (20) using domain
deletion and systematic amino acid substitution techniques,
have suggested that the LFA-1 binding region is located
within domains 1 and 2 (D1 and D2) of ICAM-1. Moreover,
the homologous ICAM-2 molecule, which 'also binds to
LFA-1, has only three immunoglobulin-like domains, corre-
sponding to D1, D2, and D3 ofthe ICAM-1 molecule (21), and
lacks the unique region in ICAM-1 defined by our studies.
These data suggest that interaction of ICAM-1 with LFA-1
involves multiple regions of the protein. While the mutagen-
esis data of Staunton et al. (20) do not cover the D4 region of
the molecule, their data do imply that binding is mediated by
FIG. 2. Inhibition studies of ICAM-1/LFA-1-dependent homotypic aggregation of Raji cells. (A) Raji cells with no peptide present.
Aggregation is clearly visible. (B) Inhibition of Raji cell aggregation by purified WEHI-CAM-1 antibody at 20 ,ug/ml. (C) Inhibition of Raji cell
aggregation by JF9 peptide at 80 ,g/ml. (D) Raji cells in the presence of control peptide JF7B at 500 ,ug/ml. Aggregation is clearly visible. Cells
were examined after 8 hr of incubation. (x 100.)
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FIG. 3. Inhibition of cytotoxic cell activity by the JF9 peptide.
Cell-mediated killing was measured by the release of 51Cr into the
medium as described previously (14). Error bars represent SEM. Bar
A, negative control, no peptide or antibody present. Bar B, positive
control, purified WEHI-CAM-1 antibody added at 20 ,ug/ml. Bar C,
negative control antibody, purified WEHI-B2 antibody added at 20
,ug/ml. Bar D, JF7B added at 100 ,ug/ml. Bar E, JF9 added at 100
,ug/ml. Bar F, JF13A added at 1001gg/ml.
discontinuous segments of the ICAM-1 sequence. The inhib-
itory properties of the unique peptide (JF9) show that the
region of the ICAM-1 molecule identified in this study is
apparently a significant component of the binding process.
The peptide analog (JF9) completely inhibited ICAM-1-
dependent cell adhesion at a concentration of 24 AuM, indi-
cating an IC50 of slO ,uM. In contrast, the Gly-Arg-Gly-Asp-
Ser peptide inhibition of fibronectin-mediated adhesion is
only half-maximally effective at 78 ,M (22). Synthesis and
testing of a panel of shorter, overlapping peptides and iso-
steric analogs should identify which residues within this
region of the ICAM-1 molecule are critical to the adhesion
process.
Several studies using monoclonal antibodies directed
against both ICAM-1 and LFA-1 have shown the specific
interaction ofthese two molecules to be ofcritical importance
in the homotypic adhesion of hemopoietic cells (17, 23), in
migration of lymphocytes (24, 25), in cell-cell contact-
mediated immune mechanisms such as T- and B-cell activa-
tion (14, 26, 27), and in certain effector functions of the
immune response, including T-cell cytotoxicity and nonspe-
cific cytotoxic cell activity (14, 26, 28). In addition to having
this pivotal role in cell-cell contact-mediated immune mech-
anisms (14, 26, 27), ICAM-1 serves as a receptor for the major
group of human rhinoviruses (29, 30) and Plasmodium fal-
ciparum-parasitized erythrocytes (18), raising the possibility
that ICAM-1 might be a target for therapy. Blocking of
ICAM-1 function may be beneficial in the treatment of
diseases such as autoimmune disorders, graft rejection, the
common cold, and malaria. It has now been shown that
polypeptide analogs of the Arg-Gly-Asp motif can block
complex in vivo adhesion processes such as those mediating
tumor metastasis (31). Given the low molar concentrations
required for inhibition by JF9, this peptide could form the
basis for the design of ICAM-1-blocking drugs.
Apart from the functional significance of these observa-
tions with respect to ICAM-1, the approach used in this study
has general applicability to the identification of functional
domains in homologous proteins that have distinct biological
activities. Our approach relies on two assumptions: (i) the
functional domain(s) is likely to be hydrophilic and (ii) there
will be no significant sequence identity in the domain(s) to
other related but functionally distinct proteins. This method
of combining a graphical analysis of the hydropathic char-
acter of a protein with sequence comparisons is a simple
means for fingerprinting putative functionally important seg-
ments of biologically active proteins. The results obtained
can be subjected to direct experimental verification by chem-
ical peptide synthesis (as used here) or by genetic engineering
with site-directed or deletion mutational analysis.
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